Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dermata Therapeutics Inc

0.7880
-0.0185-2.29%
Post-market: 0.80500.0170+2.16%19:45 EDT
Volume:101.78K
Turnover:78.52K
Market Cap:4.28M
PE:-0.05
High:0.8200
Open:0.8000
Low:0.7152
Close:0.8065
Loading ...

Company Profile

Company Name:
Dermata Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
8
Office Location:
3525 Del Mar Heights Road,Suite 332,San Diego,California,United States
Zip Code:
92130
Fax:
- -
Introduction:
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Directors

Name
Position
Gerald T. Proehl
President, Chief Executive Officer and Chairman
David Hale
Lead Director
Andrew Sandler
Director
Brittany Bradrick
Director
Kathleen Scott
Director
Mary Fisher
Director
Stephen J. Mento
Director
Wendell Wierenga
Director

Shareholders

Name
Position
Gerald T. Proehl
President, Chief Executive Officer and Chairman
Kyri K. Van Hoose
Senior Vice President, Chief Financial Officer
Maria Bedoya Toro Munera
Senior Vice President, Regulatory Affairs & Quality Assurance
Christopher J. Nardo
SVP, Chief Development Officer